Literature DB >> 28874006

Is the immune response a friend or foe for viral therapy of glioma?

Hideho Okada1, Stephen H Thorne1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28874006      PMCID： PMC5737571          DOI： 10.1093/neuonc/nox082

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Authors:  Candice Willmon; Rosa M Diaz; Phonphimon Wongthida; Feorillo Galivo; Timothy Kottke; Jill Thompson; Steven Albelda; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

Review 2.  Diplomatic immunity: turning a foe into an ally.

Authors:  Kelley A Parato; Brian D Lichty; John C Bell
Journal:  Curr Opin Mol Ther       Date:  2009-02

Review 3.  Attack, parry and riposte: molecular fencing between the innate immune system and human herpesviruses.

Authors:  V T K Le-Trilling; M Trilling
Journal:  Tissue Antigens       Date:  2015-06-10

4.  Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.

Authors:  Derek R Clements; Andra M Sterea; Youra Kim; Erin Helson; Cheryl A Dean; Anna Nunokawa; Krysta Mila Coyle; Tanveer Sharif; Paola Marcato; Shashi A Gujar; Patrick W K Lee
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

5.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

Authors:  Julie Vincent; Grégoire Mignot; Fanny Chalmin; Sylvain Ladoire; Mélanie Bruchard; Angélique Chevriaux; François Martin; Lionel Apetoh; Cédric Rébé; François Ghiringhelli
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

6.  Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines.

Authors:  U Pohl; W Wick; J Weissenberger; J P Steinbach; J Dichgans; A Aguzzi; M Weller
Journal:  Int J Oncol       Date:  1999-10       Impact factor: 5.650

7.  A vaccine targeting mutant IDH1 induces antitumour immunity.

Authors:  Theresa Schumacher; Lukas Bunse; Stefan Pusch; Felix Sahm; Benedikt Wiestler; Jasmin Quandt; Oliver Menn; Matthias Osswald; Iris Oezen; Martina Ott; Melanie Keil; Jörg Balß; Katharina Rauschenbach; Agnieszka K Grabowska; Isabel Vogler; Jan Diekmann; Nico Trautwein; Stefan B Eichmüller; Jürgen Okun; Stefan Stevanović; Angelika B Riemer; Ugur Sahin; Manuel A Friese; Philipp Beckhove; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2014-06-25       Impact factor: 49.962

8.  Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.

Authors:  Hideho Okada; Takahiko Tsugawa; Hidemitsu Sato; Naruo Kuwashima; Andrea Gambotto; Kaori Okada; Jill E Dusak; Wendy K Fellows-Mayle; Glenn D Papworth; Simon C Watkins; William H Chambers; Douglas M Potter; Walter J Storkus; Ian F Pollack
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

9.  Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.

Authors:  Leah A Mitchell; Fernando Lopez Espinoza; Daniel Mendoza; Yuki Kato; Akihito Inagaki; Kei Hiraoka; Noriyuki Kasahara; Harry E Gruber; Douglas J Jolly; Joan M Robbins
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

10.  Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.

Authors:  Kei Hiraoka; Akihito Inagaki; Yuki Kato; Tiffany T Huang; Leah A Mitchell; Shuichi Kamijima; Masamichi Takahashi; Hiroshi Matsumoto; Katrin Hacke; Carol A Kruse; Derek Ostertag; Joan M Robbins; Harry E Gruber; Douglas J Jolly; Noriyuki Kasahara
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300
  10 in total
  1 in total

Review 1.  Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies.

Authors:  Alexander F Haddad; Jacob S Young; Nikhil V Mummaneni; Noriyuki Kasahara; Manish K Aghi
Journal:  J Neurooncol       Date:  2021-01-03       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.